STipe – Harnessing the power of innate immune system
Representing a novel approach to modulate the STING pathway, STipe has the potential to revolutionise the treatment of many cancers and autoimmune diseases.
STipe is a preclinical-stage company that is developing first-in-class systemic sensitisers that target certain protein/protein interactions within the STING pathway.
Industry
Therapeutics
